Angiogenesis-related endothelial cell receptors and extracellular matrix components

Angiogenesis-related endothelial cell receptors and extracellular matrix (ECM) components represent a broad class of molecules that coordinate the development of new blood vessels from pre-existing ones. This group includes critical signaling receptors such as the Vascular Endothelial Growth Factor Receptors (VEGFR-1, -2, and -3) and Tie-2, which respond to growth factors to initiate endothelial cell proliferation and migration (Ferrara, 2004, Nature Medicine). Additionally, cell-surface integrins and structural ECM proteins like collagen and fibronectin provide the physical framework and co-signaling required for vessel assembly and stabilization (Desgrosellier & Cheresh, 2010, Nature Reviews Cancer). In diseases such as cancer and wet age-related macular degeneration, these components are pathologically exploited to support tissue growth and metabolic demands (Carmeliet, 2005, Nature). Pharmacological interventions, including monoclonal antibodies like bevacizumab and multi-kinase inhibitors like sunitinib, target these pathways to inhibit neovascularization (Ferrara & Adamis, 2016, Nature Reviews Drug Discovery). However, because these molecules also play roles in normal vascular homeostasis, their inhibition can lead to systemic side effects such as hypertension, proteinuria, and impaired wound healing (Eremina et al., 2008, New England Journal of Medicine).

Other names

Angiogenic receptors and ECM proteinsEndothelial cell surface markers and matrix componentsAngiogenesis-related targets

Inhibition of pro-angiogenic signaling pathways by blocking ligand-receptor interactions, inhibiting intracellular kinase domains, or disrupting cell-extracellular matrix adhesion.